State-licensed cannabis operators remain fully subject to one of the most punishing tax regimes applied to any legal industry in the United States - and they will stay there until federal law actually changes. A Congressional Research Service report published February 6 confirms that Internal Revenue Code Section 280E, which bars cannabis businesses from deducting ordinary operating expenses, continues to apply in full because marijuana remains a Schedule I controlled substance under federal law, regardless of what any state has authorized.
What Section 280E Actually Does - and Why It Hits So Hard
Most businesses can deduct the costs of running their operations: payroll, rent, utilities, insurance, even modest charitable contributions meant to build community goodwill. Cannabis companies cannot. Section 280E strips those deductions entirely, on the theory that a business trafficking a Schedule I substance should receive no federal tax relief on its expenses. The practical result is that cannabis operators are effectively taxed on gross profit rather than net income - a structure that can push effective federal tax rates toward 80%, according to figures cited in industry research.
There is one carve-out. The tax code does permit cannabis businesses to reduce their gross receipts by cost of goods sold - COGS - when calculating taxable income, because COGS offsets gross receipts at the gross income stage, prior to deductions. That distinction matters mechanically: calculating COGS involves adding beginning inventory to purchases and production costs, then subtracting ending inventory. In practice, though, it leaves most operating expenses entirely unshielded.
The consequences show up in the numbers. Whitney Economics estimated that only 27.3% of U.S. cannabis operators were profitable in 2024 - compared to roughly 65% of all small businesses across the broader economy. That gap is not entirely the product of 280E, but the tax burden is a primary driver. Many well-run cannabis businesses with real customers and genuine revenue operate at a federal tax loss not because their underlying economics are broken, but because Washington taxes them as if they are criminal enterprises.
The Eighth Amendment Question Nobody Has Fully Answered
Here is where it gets constitutionally interesting. The CRS report examined whether Section 280E runs afoul of the Eighth Amendment's Excessive Fines Clause - the same provision that prohibits penalties "grossly disproportional to the gravity of the offense," per the Supreme Court's 1998 ruling in United States v. Bajakajian.
The answer, at least for now: unresolved. In Northern California Small Business Assistants Inc. v. Commissioner of Internal Revenue, a 2019 U.S. Tax Court case, a California medical cannabis dispensary argued that 280E operates as a punishment rather than a neutral tax provision - and therefore constitutes an excessive fine. Ten judges held that it does not violate the Excessive Fines Clause. Three judges, notably, concluded that Section 280E does impose a fine - they simply declined to rule on whether that fine crosses the constitutional threshold into "excessive." The CRS characterizes whether 280E is a denial of a tax benefit or a form of punishment as "a matter of debate." That is a carefully worded phrase from a nonpartisan research body. It is not a dismissal.
The intellectual tension here is genuine. Section 280E was written in 1982 - fourteen years before California became the first state to authorize medical cannabis in 1996 - in explicit response to a court ruling that allowed a cocaine dealer to claim business deductions. The Senate Finance Committee's accompanying report left no ambiguity: the provision was designed to deny a benefit on public policy grounds, to avoid subsidizing drug trafficking. That framing made sense in a world where no state sanctioned cannabis and federal enforcement was consistent. Neither of those things is true anymore. The federal government has broadly declined to prosecute state-compliant cannabis businesses, and 64% of American adults favor federal legalization, according to 2025 Gallup polling. The public policy rationale undergirding 280E has aged poorly.
Reclassification Remains Stuck in Administrative Limbo
The most direct path to 280E relief runs through rescheduling. If cannabis moves from Schedule I to Schedule III under the Controlled Substances Act, the legal basis for 280E's application collapses - because 280E targets businesses trafficking Schedule I and Schedule II substances specifically. A Schedule III designation would mean cannabis companies could deduct rent, payroll, and utilities like any other American business.
President Biden's Department of Justice issued a proposed Schedule III rule in May 2024. President Trump signed an executive order on December 18 directing Attorney General Pamela Bondi to expedite reclassification. Nearly two months later, neither Bondi nor the DOJ has offered any public update on where that process stands. Expedited, in this context, has so far meant invisible.
Until the administrative machinery actually moves, cannabis operators are left holding a 280E tax bill that the federal government itself largely admits - through its own enforcement choices - is untethered from any meaningful prosecution priority. The CRS report is direct on this point: the absence of CSA enforcement "does not render Section 280E inoperable." Selective non-enforcement does not equal repeal. Cannabis businesses know this acutely. They pay the tax even as federal prosecutors largely look the other way on the underlying conduct the tax was designed to punish.
What's striking here is the asymmetry: the federal government reserves the right to tax cannabis businesses as federal criminals while simultaneously declining, in most circumstances, to treat them as such. That is not a sustainable legal posture - and the constitutional debate the CRS identified will not quietly go away.
